Evogene Q2 2024 GAAP EPS $(1.06) May Not Be Comparable To $(0.12) Estimate, Sales $914.000K Beat $800.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Evogene reported its Q2 2024 financial results with a GAAP EPS of $(1.06), which is not comparable to the $(0.12) estimate. However, the company exceeded sales expectations with $914,000 compared to the $800,000 estimate.
August 22, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evogene's Q2 2024 earnings report shows a GAAP EPS of $(1.06), which is not comparable to the $(0.12) estimate. However, the company outperformed in sales, reporting $914,000 against the $800,000 estimate.
The earnings per share (EPS) reported by Evogene is significantly different from the estimate, which may cause uncertainty among investors. However, the sales figures exceeded expectations, which could offset some of the negative sentiment from the EPS discrepancy. Overall, the mixed results may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100